Irina B. Vinogradova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina B. Vinogradova has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
19 shared publications - Olga B. Nesmeyanova
Chelyabinsk Regional Clinical Hospital
13 shared publications - Vadim I. Mazurov
Organizational and Methodological Department, North-Western State Medical University Named After I.I. Mechnikov, 41, Kirochnaya St., Saint Petersburg 191015, Russia
12 shared publications - D. G. Krechikova
Clinical Hospital “RZD-Medicine” of Smolensk
11 shared publications - O. N. Anoshenkova
Tomsk Regional Clinical Hospital
11 shared publications - Rusana R. Samigullina
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
10 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Non-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Open AccessNon-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- Open Access
- 1 November 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (5) , 463-476
Extract of oak bark as a selective natural reagent for the spectrophotometric determination of iron (II) in pharmaceutical preparations and blood serum
Interleukin 6 (IL-6) plays a key role in the immunopathogenesis of rheumatoid arthritis (RA), with the pleiotropic effect on organs and tissues. Blocking IL-6 receptors is of interest both in terms of correcting joint syndrome and alleviating systemic inflammation. Levilimab (LVL) is a monoclonal antibody drug against the interleukin 6 receptor, which has demonstrated efficacy and safety in patients with active RA when administered 162 mg subcutaneously (SC) every week. The article presents data obtained from the two-phase clinical study (CS) LUNAR (NCT05800327), in which the first stage was a CS phase I, and the second – CS phase III. The aim is to study the tolerability, safety, immunogenicity and main pharmacokinetic and pharmacodynamic parameters of the LVL after its single SC or intravenous (IV) administration in increasing doses to healthy volunteers, as well as to confirm the efficacy and safety of new dosing regimens of LVL at a dose of 648 mg IV once every 4 weeks (Q4W) in combination with methotrexate (MT) and at a dose of 324 mg SC once every 2 weeks (Q2W) in combination with MT in patients with active RA resistant to MT monotherapy. Materials and methods. During the first stage of clinical trial, the safety and tolerance of new regimens of LVL 648 mg Q4W IV and 324 mg Q2W SC were demonstrated in healthy volunteers and these doses have also been shown to provide the required therapeutic concentration throughout the entire interdose interval. In the phase III study, patients with active RA (according to American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) 2010 criteria) resistant to MT therapy at a stable dose of 15–25 mg/week for ≥12 weeks were included.The study had a double-blind design until week 24, evaluation of the efficacy of LVL new dosing regimens with the standard regimen of 162 mg SC QW was conducted at week 24 based on the parameter “Proportion of patients achieving low RA activity according to DAS28-ESR (Disease Activity Score with Erythrocyte Sedimentation Rate) Results. 232 patients were randomized into one of the LVL application groups: 162 mg SC QW (n=78), 324 mg SC Q2W (n=77), and 648 mg IV Q4W (n=77). At week 24, the groups with 324 mg SC Q2W and 648 mg IV Q4W demonstrated non-inferior efficacy in terms of the “Percentage of patients achieving low activity according to DAS28- ESR”: 68.8% and 63.4%, respectively, compared to 62.6% in the 162 mg SC QW group (p=0.8277 and p=0.3954). The efficacy analysis for secondary endpoints (achievement of remission and low RA activity according to DAS28- ESR, DAS28-CRP, CDAI, SDAI, achievement of ACR20/ACR50/ACR70, dynamics of ESR and CRP) also demonstrated comparable efficacy of the new dose regimens of LVL.At week 24, more than 39% of patients in all groups achieved RA remission according to DAS28-ESR and were switched to a maintenance regimen of the drug, while by week 52 of therapy, the vast majority of patients maintained RA remission according to DAS28-ESR, as well as the relative number of patients with RA remission according to DAS28-CRP, CDAI, and SDAI indices increased. In cases where RA remission according to DAS28-ESR was not achieved at week 24, continuation of initial LVL therapy led to achieving low activity and RA remission in a significant number of cases (up to 45.8% according to DAS28-ESR) by week 52. The most of AEs and ARs were mild and moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). The use LVL new dosing regimens was accompanied by a favorable and predictable safety profile. Conclusion. The efficacy and safety of LVL at a dose of 648 mg IV once every 4 weeks and 324 mg SC once every 2 weeks are comparable to the previously approved dosing regimen. Transitioning to maintenance therapy upon achieving RA remission is accompanied by the retention rate of clinical response.
- 1 November 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (5) , 463-476
Open AccessExtract of oak bark as a selective natural reagent for the spectrophotometric determination of iron (II) in pharmaceutical preparations and blood serum
Interleukin 6 (IL-6) plays a key role in the immunopathogenesis of rheumatoid arthritis (RA), with the pleiotropic effect on organs and tissues. Blocking IL-6 receptors is of interest both in terms of correcting joint syndrome and alleviating systemic inflammation. Levilimab (LVL) is a monoclonal antibody drug against the interleukin 6 receptor, which has demonstrated efficacy and safety in patients with active RA when administered 162 mg subcutaneously (SC) every week. The article presents data obtained from the two-phase clinical study (CS) LUNAR (NCT05800327), in which the first stage was a CS phase I, and the second – CS phase III. The aim is to study the tolerability, safety, immunogenicity and main pharmacokinetic and pharmacodynamic parameters of the LVL after its single SC or intravenous (IV) administration in increasing doses to healthy volunteers, as well as to confirm the efficacy and safety of new dosing regimens of LVL at a dose of 648 mg IV once every 4 weeks (Q4W) in combination with methotrexate (MT) and at a dose of 324 mg SC once every 2 weeks (Q2W) in combination with MT in patients with active RA resistant to MT monotherapy. Materials and methods. During the first stage of clinical trial, the safety and tolerance of new regimens of LVL 648 mg Q4W IV and 324 mg Q2W SC were demonstrated in healthy volunteers and these doses have also been shown to provide the required therapeutic concentration throughout the entire interdose interval. In the phase III study, patients with active RA (according to American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) 2010 criteria) resistant to MT therapy at a stable dose of 15–25 mg/week for ≥12 weeks were included.The study had a double-blind design until week 24, evaluation of the efficacy of LVL new dosing regimens with the standard regimen of 162 mg SC QW was conducted at week 24 based on the parameter “Proportion of patients achieving low RA activity according to DAS28-ESR (Disease Activity Score with Erythrocyte Sedimentation Rate) Results. 232 patients were randomized into one of the LVL application groups: 162 mg SC QW (n=78), 324 mg SC Q2W (n=77), and 648 mg IV Q4W (n=77). At week 24, the groups with 324 mg SC Q2W and 648 mg IV Q4W demonstrated non-inferior efficacy in terms of the “Percentage of patients achieving low activity according to DAS28- ESR”: 68.8% and 63.4%, respectively, compared to 62.6% in the 162 mg SC QW group (p=0.8277 and p=0.3954). The efficacy analysis for secondary endpoints (achievement of remission and low RA activity according to DAS28- ESR, DAS28-CRP, CDAI, SDAI, achievement of ACR20/ACR50/ACR70, dynamics of ESR and CRP) also demonstrated comparable efficacy of the new dose regimens of LVL.At week 24, more than 39% of patients in all groups achieved RA remission according to DAS28-ESR and were switched to a maintenance regimen of the drug, while by week 52 of therapy, the vast majority of patients maintained RA remission according to DAS28-ESR, as well as the relative number of patients with RA remission according to DAS28-CRP, CDAI, and SDAI indices increased. In cases where RA remission according to DAS28-ESR was not achieved at week 24, continuation of initial LVL therapy led to achieving low activity and RA remission in a significant number of cases (up to 45.8% according to DAS28-ESR) by week 52. The most of AEs and ARs were mild and moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). The use LVL new dosing regimens was accompanied by a favorable and predictable safety profile. Conclusion. The efficacy and safety of LVL at a dose of 648 mg IV once every 4 weeks and 324 mg SC once every 2 weeks are comparable to the previously approved dosing regimen. Transitioning to maintenance therapy upon achieving RA remission is accompanied by the retention rate of clinical response.
- Open Access
- 2 July 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (3) , 253-261
Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study
Under real-world clinical practice together with indices for assessing disease activity and the effectiveness of therapy, drug retention provides critical information on efficacy, safety, compliance and convenience of use.The aim – to obtain data on the safety of netakimab (NTK) in a population of patients with ankylosing spondylitis (AS), including various somatic diseases, as well as to assess retention on therapy during 2 years of observation in real word clinical practice.Materials and methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included 137 patients who were prescribed netakimab therapy before enrollment. Clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, 52, 76, 104 weeks of therapy were collected within the study. The average age of the patients 42,3 y. O., 34.3% of them with previous biologics therapy.Results. Median observation period was 104 weeks (range 1–137 weeks). At the end of the analyzed period (104 weeks of therapy), 85,5% [95% confidence interval (95% CI): 79.7–91.8] of patients continued treatment with Netakimab. Retention on NTK therapy was slightly better in “bio-naïve” vs patients who received biologics earlier: 88.7% (95% CI: 82.3–95.5) and 78.9% (95% CI: 67.5–92.2), respectively, without significant differences between groups (p=0.16). 21 (15.3%) patients withdrew from study before visit 6. The main end of study reasons was lost to follow-up – 7 (5.1%) patients, and treatment inefficacy – 6 (4.4%) patients. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein) showed statistically significant decreases from baseline: by three times during the first 3 months of therapy and two times decrease during the first year of treatment. This trend continued in the second year of treatment, although with a lower rate of reduction. By week 104 of therapy, 52.9% (95% CI: 47.3–58.4) reached low disease activity (1.3≤ASDASConclusions. In real-world clinical practice, 85.5% of patients continued treatment with Netakimab at the end of 104 weeks. By 104 weeks 74% patients had low disease activity or inactive disease. Netakimab was well tolerated by most of patients.
- 2 July 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (3) , 253-261
Open AccessReal-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study
Under real-world clinical practice together with indices for assessing disease activity and the effectiveness of therapy, drug retention provides critical information on efficacy, safety, compliance and convenience of use.The aim – to obtain data on the safety of netakimab (NTK) in a population of patients with ankylosing spondylitis (AS), including various somatic diseases, as well as to assess retention on therapy during 2 years of observation in real word clinical practice.Materials and methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included 137 patients who were prescribed netakimab therapy before enrollment. Clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, 52, 76, 104 weeks of therapy were collected within the study. The average age of the patients 42,3 y. O., 34.3% of them with previous biologics therapy.Results. Median observation period was 104 weeks (range 1–137 weeks). At the end of the analyzed period (104 weeks of therapy), 85,5% [95% confidence interval (95% CI): 79.7–91.8] of patients continued treatment with Netakimab. Retention on NTK therapy was slightly better in “bio-naïve” vs patients who received biologics earlier: 88.7% (95% CI: 82.3–95.5) and 78.9% (95% CI: 67.5–92.2), respectively, without significant differences between groups (p=0.16). 21 (15.3%) patients withdrew from study before visit 6. The main end of study reasons was lost to follow-up – 7 (5.1%) patients, and treatment inefficacy – 6 (4.4%) patients. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein) showed statistically significant decreases from baseline: by three times during the first 3 months of therapy and two times decrease during the first year of treatment. This trend continued in the second year of treatment, although with a lower rate of reduction. By week 104 of therapy, 52.9% (95% CI: 47.3–58.4) reached low disease activity (1.3≤ASDASConclusions. In real-world clinical practice, 85.5% of patients continued treatment with Netakimab at the end of 104 weeks. By 104 weeks 74% patients had low disease activity or inactive disease. Netakimab was well tolerated by most of patients.
- 11 May 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 522 (1) , 387-403
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
The study aims to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of seniprutug (BCD-180) in patients with active radiographic axial spondyloarthritis (r-axSpA, or ankylosing spondylitis). . Two hundred sixty patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups to receive either seniprutug (BCD-180) 5 or 7 mg/kg, or placebo. BCD-180 was administered in the respective group dose using a 0–12–36 week regimen. The placebo group patients were switched to BCD-180 5 mg/kg at Week 24, with therapy continued at Week 36. The primary endpoint was the proportion of patients achieving 40% improvement in the Assessment in Spondyloarthritis International Society (ASAS40) score at Week 24. The secondary endpoints included the proportion of patients achieving an ASAS20/40 response, improvement in 5 of 6 ASAS criteria (ASAS5/6), partial remission according to ASAS, ASDAS-CRP clinically important improvement in (Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, ASDAS-CII) and ASDAS-CRP major improvement (ASDAS-MI). An analysis of changes over time in the disease activity status according to ASDAS-CRP, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, as well as changes over time in laboratory markers (CRP and erythrocyte sedimentation rate (ESR)) was also conducted. Safety was assessed based on the frequency and profile of adverse events (AE) and adverse reactions (AR). The proportion of patients who achieved an ASAS40 response at Week 24 on seniprutug (BCD-180) at doses of 7 and 5 mg/kg was 51.4 and 40.8%, respectively, compared with 24% in the Placebo group (p = 0.0012 and p = 0.0417, respectively). Analysis of secondary endpoints showed that the efficacy of BCD-180 at both study doses was statistically significantly superior to placebo in patients with r-axSpA at Week 24 in the following respects: reduction in the proportion of subjects with very high disease activity (ASDAS-CRP > 3.5), achieving ASDAS-CII, ASAS20, ASAS5/6 response. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI score, as well as CRP and ESR levels was demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. The most common AEs were infusion-related reactions, most of which were mild to moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed mainly during the first administration. The proportion of patients with detected binding antibodies was 5.1%. No neutralizing antibodies were detected. . Seniprutug (BCD-180) as a therapy for r-axSpA has demonstrated superiority over placebo in the clinical efficacy, a good safety profile and low immunogenicity.
- 11 May 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 522 (1) , 387-403
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA
The study aims to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of seniprutug (BCD-180) in patients with active radiographic axial spondyloarthritis (r-axSpA, or ankylosing spondylitis). . Two hundred sixty patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups to receive either seniprutug (BCD-180) 5 or 7 mg/kg, or placebo. BCD-180 was administered in the respective group dose using a 0–12–36 week regimen. The placebo group patients were switched to BCD-180 5 mg/kg at Week 24, with therapy continued at Week 36. The primary endpoint was the proportion of patients achieving 40% improvement in the Assessment in Spondyloarthritis International Society (ASAS40) score at Week 24. The secondary endpoints included the proportion of patients achieving an ASAS20/40 response, improvement in 5 of 6 ASAS criteria (ASAS5/6), partial remission according to ASAS, ASDAS-CRP clinically important improvement in (Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, ASDAS-CII) and ASDAS-CRP major improvement (ASDAS-MI). An analysis of changes over time in the disease activity status according to ASDAS-CRP, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, as well as changes over time in laboratory markers (CRP and erythrocyte sedimentation rate (ESR)) was also conducted. Safety was assessed based on the frequency and profile of adverse events (AE) and adverse reactions (AR). The proportion of patients who achieved an ASAS40 response at Week 24 on seniprutug (BCD-180) at doses of 7 and 5 mg/kg was 51.4 and 40.8%, respectively, compared with 24% in the Placebo group (p = 0.0012 and p = 0.0417, respectively). Analysis of secondary endpoints showed that the efficacy of BCD-180 at both study doses was statistically significantly superior to placebo in patients with r-axSpA at Week 24 in the following respects: reduction in the proportion of subjects with very high disease activity (ASDAS-CRP > 3.5), achieving ASDAS-CII, ASAS20, ASAS5/6 response. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI score, as well as CRP and ESR levels was demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. The most common AEs were infusion-related reactions, most of which were mild to moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed mainly during the first administration. The proportion of patients with detected binding antibodies was 5.1%. No neutralizing antibodies were detected. . Seniprutug (BCD-180) as a therapy for r-axSpA has demonstrated superiority over placebo in the clinical efficacy, a good safety profile and low immunogenicity.
- Open Access
- 1 May 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (2) , 158-167
The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods. Patients with SS according to ACR/EULAR (American College of Rheumatology/ European Alliance of Associations for Rheumatology) 2013 criteria with modified Rodnan skin score (mRSS) ≥10 and ≲20 and forced vital capacity (FVC) ≥40% from the due took part in the study. Infusions of DIV 250 mg were administered on weeks 0 and 2, and DIV 500 mg – on week 24 with the subsequent use in open mode, starting from week 48. This publication presents data obtained for 48 weeks of trial (before the DIV infusion at week 48). Primary endpoint was the change in the mRSS from baseline to week 48. The dynamic of FVC was estimated as the secondary endpoint. The safety evaluation included the frequency and profile of adverse events and adverse reactions (ARs). Immunogenicity was assessed by detection of binding and neutralizing anti-drug antibodies on weeks 2, 24 and 48.Results. 151 patients were randomized into two groups: DIV (n=76) and Placebo (n=75). The most were female; the median duration of the disease was about 3–4 years. The initial value of the mRSS was 14 and 13 points in DIV and PBO groups, respectively. The change of mRSS from baseline to week 48 was –5.8±1.1 points in DIV group and –2.7±1.0 points in Placebo group (adjusted mean difference (AMD) with 95% confidence interval –3.1 (–4.5; –1.7); pConclusion. Divosilimab has demonstrated a significant decrease in severity of skin fibrosis, a positive effect on the respiratory function and a favorable safety profile, which allows to consider it as a promising therapeutic option for SS.
- 1 May 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (2) , 158-167
Open AccessThe efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS
The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods. Patients with SS according to ACR/EULAR (American College of Rheumatology/ European Alliance of Associations for Rheumatology) 2013 criteria with modified Rodnan skin score (mRSS) ≥10 and ≲20 and forced vital capacity (FVC) ≥40% from the due took part in the study. Infusions of DIV 250 mg were administered on weeks 0 and 2, and DIV 500 mg – on week 24 with the subsequent use in open mode, starting from week 48. This publication presents data obtained for 48 weeks of trial (before the DIV infusion at week 48). Primary endpoint was the change in the mRSS from baseline to week 48. The dynamic of FVC was estimated as the secondary endpoint. The safety evaluation included the frequency and profile of adverse events and adverse reactions (ARs). Immunogenicity was assessed by detection of binding and neutralizing anti-drug antibodies on weeks 2, 24 and 48.Results. 151 patients were randomized into two groups: DIV (n=76) and Placebo (n=75). The most were female; the median duration of the disease was about 3–4 years. The initial value of the mRSS was 14 and 13 points in DIV and PBO groups, respectively. The change of mRSS from baseline to week 48 was –5.8±1.1 points in DIV group and –2.7±1.0 points in Placebo group (adjusted mean difference (AMD) with 95% confidence interval –3.1 (–4.5; –1.7); pConclusion. Divosilimab has demonstrated a significant decrease in severity of skin fibrosis, a positive effect on the respiratory function and a favorable safety profile, which allows to consider it as a promising therapeutic option for SS.
- Open Access
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 39-49
Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 39-49
Open AccessUse of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.
- Open Access
- 2 March 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (1) , 55-63
Efficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis. Results of the multicenter “METEOR” study
The aim of the study – to analyze the effectiveness and tolerability of subcutaneous methotrexate (sc MTX) (Metorthrit; S.C. Rompharm Company S.R.L) in patients with rheumatoid arthritis (RA) with high disease activity and rapid dose escalation, to assess their quality of life (QoL) in real clinical practice.Material and methods. The study included 105 patients, mostly women, with a reliable diagnosis of RA with high disease activity (DAS-28 (Disease Activity Score 28) ≥5.1) aged 18 years and older and ineffectiveness of previous oral MTX therapy for at least 6 months or who had not received MTX. Sc MTX therapy was started at a dose of 15 mg/weekly. During the first month of therapy, a rapid escalation of the sc MTX dose of 2.5 mg/week was performed once a week. until the dose of 22.5 mg/week was reached, then, with insufficient response, the dose of sc MTX could be increased to 25 mg/week. The evaluation of the effectiveness of therapy, functional status, and QoL was carried out after 4–12–18–24 weeks.Results. After a rapid escalation of the sc MTX dose during the first month of the study, at all stages of follow-up, a rapid decrease in disease activity was noted for all standard indices (DAS-28 – from 5.8±0.75 to 2.93±1.05; CDAI (Clinical Disease Activity Score) – from 30.13±8.33 to 7.08±6.07; SDAI (Simplified Disease Activity Score) – from 32.78±9.64 to 7.48±6.53) and the activity index, which was evaluated by the patients themselves (RAPID-3 (Routine Assessment of Patient Index Data 3) from 16.18±4.6 to 5.56±4.66; p≤0.05). The number of patients with high disease activity according to DAS-28 decreased by 2 times by the week 4 of therapy (to 46.2%), after 12 weeks they remained 13.3%, and by week 24 high activity remained only in 4.4% of patients. There was a marked decrease in pain from 65.6±13.07 to 20.5±17.1 mm in VAS (Visual Analogue Score) (ppppp0.05), however, the number of infections in patients receiving GC was significantly higher (9.5% and 0.0%, respectively; p=0.009). The need for nonsteroidal anti-inflammatory drugs (NSAIDs) at the beginning of the study was in 93.2% of patients on average 21.1 days per month, after 24 weeks, the need for NSAIDs was in 54.4% of patients on average 3.8 days per month. In general, the safety profile of MTX was acceptable.Conclusion. With high RA activity, the tactics of starting therapy with sc MTX at a dose of 15 mg per week and a rapid escalation of its dose of 2.5 mg weekly to 22.5–25 mg/week, allows achieving therapy goals by 3 months in 17.8% of patients, and by 6 months in 54.5%, to quickly improve the QoL, reduce the level of pain, reduce the dose of GC by 3 months of therapy or completely cancel them, reduce the need for NSAIDs by 7 times with an acceptable level of therapy safety.
- 2 March 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (1) , 55-63
Open AccessEfficacy and safety of rapid dose escalation of methotrexate in rheumatoid arthritis. Results of the multicenter “METEOR” study
The aim of the study – to analyze the effectiveness and tolerability of subcutaneous methotrexate (sc MTX) (Metorthrit; S.C. Rompharm Company S.R.L) in patients with rheumatoid arthritis (RA) with high disease activity and rapid dose escalation, to assess their quality of life (QoL) in real clinical practice.Material and methods. The study included 105 patients, mostly women, with a reliable diagnosis of RA with high disease activity (DAS-28 (Disease Activity Score 28) ≥5.1) aged 18 years and older and ineffectiveness of previous oral MTX therapy for at least 6 months or who had not received MTX. Sc MTX therapy was started at a dose of 15 mg/weekly. During the first month of therapy, a rapid escalation of the sc MTX dose of 2.5 mg/week was performed once a week. until the dose of 22.5 mg/week was reached, then, with insufficient response, the dose of sc MTX could be increased to 25 mg/week. The evaluation of the effectiveness of therapy, functional status, and QoL was carried out after 4–12–18–24 weeks.Results. After a rapid escalation of the sc MTX dose during the first month of the study, at all stages of follow-up, a rapid decrease in disease activity was noted for all standard indices (DAS-28 – from 5.8±0.75 to 2.93±1.05; CDAI (Clinical Disease Activity Score) – from 30.13±8.33 to 7.08±6.07; SDAI (Simplified Disease Activity Score) – from 32.78±9.64 to 7.48±6.53) and the activity index, which was evaluated by the patients themselves (RAPID-3 (Routine Assessment of Patient Index Data 3) from 16.18±4.6 to 5.56±4.66; p≤0.05). The number of patients with high disease activity according to DAS-28 decreased by 2 times by the week 4 of therapy (to 46.2%), after 12 weeks they remained 13.3%, and by week 24 high activity remained only in 4.4% of patients. There was a marked decrease in pain from 65.6±13.07 to 20.5±17.1 mm in VAS (Visual Analogue Score) (ppppp0.05), however, the number of infections in patients receiving GC was significantly higher (9.5% and 0.0%, respectively; p=0.009). The need for nonsteroidal anti-inflammatory drugs (NSAIDs) at the beginning of the study was in 93.2% of patients on average 21.1 days per month, after 24 weeks, the need for NSAIDs was in 54.4% of patients on average 3.8 days per month. In general, the safety profile of MTX was acceptable.Conclusion. With high RA activity, the tactics of starting therapy with sc MTX at a dose of 15 mg per week and a rapid escalation of its dose of 2.5 mg weekly to 22.5–25 mg/week, allows achieving therapy goals by 3 months in 17.8% of patients, and by 6 months in 54.5%, to quickly improve the QoL, reduce the level of pain, reduce the dose of GC by 3 months of therapy or completely cancel them, reduce the need for NSAIDs by 7 times with an acceptable level of therapy safety.
- Open Access
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Open AccessExperience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
- Open Access
- 14 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 44-48
Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.
- 14 February 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (1) , 44-48
Open AccessEfficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS
The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.